Hexarelin is a synthetic hexapeptide that acts on the ghrelin receptor (GHS-R1a), which places it in the growth hormone releasing peptide class alongside GHRP-2, GHRP-6, and ipamorelin rather than with the GHRH analogs. The published record describes it as one of the highest-amplitude acute growth hormone releasers per microgram in that class, and in the same breath as one of the fastest to desensitize and one of the least selective. Hexarelin is not FDA-approved; among the compounds it gets measured against, only tesamorelin, a GHRH analog, carries an FDA-approved indication.
Hexarelin is a GHS-R1a agonist whose high acute growth hormone amplitude is offset by faster receptor desensitization and greater cortisol, ACTH, and prolactin co-stimulation than ipamorelin, and it holds no FDA approval.
The literature sorts these compounds by the receptor they bind, and that single fact predicts most of what follows about potency, side profile, and route of administration. Hexarelin sits in the growth hormone releasing peptide bucket: ghrelin mimetics that act on GHS-R1a in the pituitary and hypothalamus. Getting the bucket right is what keeps a comparison honest, since compounds drawn from all three groups share little beyond the hormone they end up releasing.
| Criteria | GHRPs (Hexarelin, GHRP-2, GHRP-6, ipamorelin) | GHRH analogs (sermorelin, tesamorelin, CJC-1295) | Oral non-peptide (MK-677) |
|---|---|---|---|
| Receptor | GHS-R1a, the ghrelin receptor | GHRH receptor | GHS-R1a, the ghrelin receptor |
| Molecule and route | Peptide, injected | Peptide, injected | Small molecule, oral |
| Release shape | Forceful pulse, blunts somatostatin | Physiologic pulse, feedback intact | Sustained, around-the-clock elevation |
| US regulatory status | None FDA-approved | Tesamorelin FDA-approved; the others not | Not FDA-approved |
Growth hormone secretagogues fall into three groups: ghrelin-receptor peptides including Hexarelin, GHRP-2, GHRP-6, and ipamorelin; GHRH-receptor analogs including sermorelin, tesamorelin, and CJC-1295; and orally active non-peptide ghrelin-receptor agonists, of which ibutamoren (MK-677) is the leading example.
The potency ranking that circulates for these peptides describes a single dose, not a course of them. Acute research measures the size of the growth hormone spike in blood over the first one to two hours after one administration, and on that metric Hexarelin and GHRP-2 sit at the top of the peptide class. It is the number quoted most often and the one that travels furthest from its context, because it says nothing about what the same dose does on day ten.
On a per-microgram basis in acute testing, Hexarelin ranks at or slightly above GHRP-2 and clearly above GHRP-6 for growth hormone release, but that ranking is measured from a single dose and narrows across repeated dosing as the receptor desensitizes.
Two doors open onto the same pituitary cell, and which one a compound knocks on decides the shape of the response. Hexarelin binds GHS-R1a, the ghrelin receptor, while sermorelin and CJC-1295 bind the GHRH receptor, a separate target on the same somatotroph cells. That difference is why the two classes are studied as a pair rather than as substitutes: given together, growth hormone output is markedly greater than the sum of either alone, since one class pushes the accelerator while the other lifts the brake.
| Criteria | Hexarelin (GHRP) | Sermorelin / CJC-1295 (GHRH analogs) |
|---|---|---|
| Receptor bound | GHS-R1a, the ghrelin receptor | GHRH receptor |
| Action on somatostatin | Blunts the inhibitory signal | No direct blunting |
| Release shape | Larger, more forceful pulse | Self-limiting, feedback preserved |
| US regulatory status | Not FDA-approved | Neither is an FDA-approved marketed product |
Hexarelin acts at the ghrelin receptor GHS-R1a and blunts somatostatin, while sermorelin and CJC-1295 act at the separate GHRH receptor and leave the body's negative feedback loops intact, which is why the literature combines the two classes rather than swapping one for the other.
Desensitization is the comparative weak point in Hexarelin's file. Research documents the growth hormone response falling substantially within days to a couple of weeks of continued frequent dosing, faster and more sharply than with a gentler peptide like ipamorelin or with the GHRH analogs. The same receptor engagement that produces the large day-one number is what drives the receptor to withdraw from the surface.
Hexarelin is documented as one of the most desensitization-prone secretagogues, with the growth hormone response falling substantially within days to roughly two weeks of continued frequent dosing, faster than with ipamorelin or the GHRH analogs.
Selectivity is where Hexarelin reads worst against its cleaner relatives. The ghrelin receptor sits near the pathways that govern ACTH, cortisol, and prolactin, so a peptide that hits that receptor hard spills over into hormones nobody was aiming at. The spillover is dose-dependent, which matters for how the comparison is read, but it is the whole reason ipamorelin exists in this literature as a named contrast.
Hexarelin and GHRP-2 produce a measurable, dose-dependent rise in ACTH, cortisol, and prolactin that GHRP-6 shows less strongly at its smaller doses and that ipamorelin, the selective member of the class, largely does not produce at all.
Hexarelin is the one secretagogue in this group with a research file about the heart rather than the pituitary. Laboratory studies report direct cardiovascular actions that appear independent of the growth hormone it releases, including effects on cardiac contractility and a protective signal in heart tissue under stress in animal models. That work is preclinical, and it cuts both ways: it is what makes Hexarelin scientifically distinctive among the secretagogues, and it is also an off-target action on the heart.
Hexarelin shows growth-hormone-independent cardiovascular activity in animal models, attributed to cardiac binding sites including the CD36 scavenger receptor, an effect partly shared by GHRP-6 but not characteristic of ipamorelin or the GHRH analogs and not demonstrated in human clinical trials.
MK-677 and Hexarelin reach for the same ghrelin receptor and arrive by opposite routes. Ibutamoren is a non-peptide small molecule built to survive stomach acid, so it works taken by mouth and holds growth hormone and IGF-1 elevated around the clock from a single daily dose, while Hexarelin is a peptide that digestion would destroy and its signal is a sharp pulse that fades. Neither is FDA-approved, and the trade sits between oral convenience with continuous stimulation on one side, and injection with faster tolerance on the other.
| Criteria | Hexarelin | MK-677 (ibutamoren) |
|---|---|---|
| Molecule and route | Peptide, injected | Non-peptide small molecule, oral |
| Growth hormone signal | Sharp, short-lived pulse | Broad elevation sustained around the clock |
| Reported drawbacks | Fast receptor desensitization; cortisol and prolactin rise | Fluid retention, appetite increase, lethargy, raised blood sugar |
| US regulatory status | Not FDA-approved | Not FDA-approved |
MK-677 is an orally active non-peptide that sustains growth hormone and IGF-1 elevation around the clock at the cost of fluid retention, lethargy, and raised blood sugar, while injected Hexarelin delivers a sharper, more pulsatile release that fades to receptor desensitization, and neither compound is FDA-approved.
Regulatory standing is where this family splits hardest. Hexarelin was developed in the 1990s and taken into clinical research for its growth hormone releasing properties and later its cardiovascular ones, then stopped short of approval, which is the ordinary outcome for the GHRP class. The distance between an approved medicine and a research chemical is the distance between a regulated manufacturing standard and none at all.
Hexarelin, GHRP-2, GHRP-6, ipamorelin, and MK-677 are unapproved research compounds with no approved human dosing and no regulated manufacturing standard for therapeutic use, and all are prohibited in competitive sport, while tesamorelin is the only secretagogue among their comparators to hold an FDA-approved indication.
Educational use only. This article describes what the published scientific and clinical literature reports about Hexarelin and other growth hormone secretagogues. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
